Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Ethnopharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1522146

5-deoxy-rutaecarpine protects against LPS-induced acute lung injury via inhibiting NLRP3 inflammasome-related inflammation

Provisionally accepted
Jinque Luo Jinque Luo *Xin Li Xin Li Li Zhang Li Zhang Meijing Deng Meijing Deng Jieyang Zhao Jieyang Zhao Jinghuan Zhang Jinghuan Zhang Wenyu Tang Wenyu Tang Qinghua Guo Qinghua Guo Ling Wang Ling Wang
  • College of Pharmacy, Changsha Medical University, Changsha, China

The final, formatted version of the article will be published soon.

    Acute lung injury (ALI) induced by lipopolysaccharide (LPS) is a significant medical condition characterized by severe pulmonary inflammation and tissue damage. NLRP3 inflammasome-driven inflammation is essential in ALI pathogenesis, inspiring novel therapeutic strategies that focus on NLRP3 and inflammation. In this study, we investigated the therapeutic potential of 5-deoxy-rutaecarpine (5-DR), a rutaecarpine derivative, in attenuating LPS-induced ALI. 5-DR treatment significantly reduced lung edema, inflammatory cell infiltration in mice with LPS burden, and reduced the levels of inflammatory mediators like interleukin-1β in the mice and in LPS-stimulated J774A.1 mouse macrophages. Further western blotting analysis showed 5-DR decreased the levels of NLRP3, cleaved caspase-1, and mature IL-1β in mice and J774A.1 cells exposed to LPS. Additionally, NF-κB pathway activation significantly diminished the inhibition of the NLRP3 inflammasome by 5-DR. Collectively, our findings highlight the therapeutic potential of 5-DR as a promising candidate for treating LPS-induced ALI, offering insights into its underlying mechanism that targets NLRP3 inflammasome-mediated inflammation.

    Keywords: 5-DR, Acute Lung Injury, lipopolysaccharide, Inflammation, NLRP3 inflammasome

    Received: 05 Nov 2024; Accepted: 10 Jan 2025.

    Copyright: © 2025 Luo, Li, Zhang, Deng, Zhao, Zhang, Tang, Guo and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jinque Luo, College of Pharmacy, Changsha Medical University, Changsha, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.